greeksoup/ stock research

CVS Health (CVS) FY2025 results: revenue $402.1 billion, up 7.8% on the year

CVS Health Corp. (CVS) reported revenue of $402.1 billion for fiscal 2025, the year ended 31 December 2025, up 7.8% on the year before. Net income was $1.8 billion, down 61.7%, and diluted earnings per share $1.39. The figures are the company's own, from the 10-K it filed with the SEC on 10 February 2026.

Revenue
$402.1 billion
+7.8% on the year
FY2018FY2025
Operating margin
1.2%
2.3% a year earlier
FY2018FY2025
Net income
$1.8 billion
-61.7% on the year
FY2018FY2025
Diluted EPS
$1.39
-62.0% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The year in brief

What management said about the year

Guidance figures: 1 lowered, 2 kept.

  • Fourth-quarter revenue rose 8.2%: Revenue was $105.7 billion, against $97.7 billion a year earlier. GAAP diluted EPS was $2.30 versus $1.30, and Adjusted EPS was $1.09 versus $1.19.
  • Adjusted EPS fell on Health Care Benefits: Management attributed the fourth-quarter Adjusted EPS decline to lower adjusted operating income in the Health Care Benefits segment.
  • Full-year medical benefit ratio improved: The MBR was 91.2% for the year against 92.5%, and full-year adjusted operating income was $2.9 billion against $0.3 billion. Favorable prior-year development of $2.0 billion contributed.
  • Goodwill impairment of $5.7 billion: Full-year operating income absorbed a $5.7 billion goodwill impairment on the Health Care Delivery unit within the Health Services segment. It is excluded from adjusted figures.
  • Operating cash flow reached $10.6 billion: Full-year cash flow from operations was $10.6 billion against $9.1 billion in 2024.
Read the Q4 FY2025 earnings call summary

From this 10-K

CVS Health is a health solutions company that connects insurance, pharmacy benefits management and retail pharmacy inside one group. At 31 December 2025 it had approximately 9,000 retail locations, more than 1,000 walk-in and primary care medical clinics and a pharmacy benefits manager with approximately 87 million plan members, and it served an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services. There are four reportable segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate/Other. The company states that its strategy is focused on simplifying health care experiences, improving engagement, lowering costs and delivering better health outcomes.

CVS Health Corp., the 10-K for 2025

CVS Health is a health solutions company that connects insurance, pharmacy benefits management and retail pharmacy inside one group. At 31 December 2025 it had approximately 9,000 retail locations, more than 1,000 walk-in and primary care medical clinics and a pharmacy benefits manager with approximately 87 million plan members, and it served an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services. There are four reportable segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate/Other. The company states that its strategy is focused on simplifying health care experiences, improving engagement, lowering costs and delivering better health outcomes.

Health Care Benefits

The segment runs the Aetna operations and offers medical, pharmacy, dental and behavioural health plans, medical management, Medicare Advantage and Medicare Supplement plans, standalone Medicare Part D prescription drug plans and Medicaid health care management services. Members reach those products through employer groups, government-sponsored plans or individually. Products where the company takes all or most of the risk for medical and dental care costs are called Insured; those where the plan sponsor takes that risk are administrative services contracts. Commercial medical products include point-of-service, preferred provider organisation, health maintenance organisation and indemnity plans, health savings accounts, consumer-directed plans and medical stop loss cover for employers that self-insure. The filing describes the industry as highly competitive, with many for-profit and not-for-profit competitors, continual new products, new entrants and consolidation.

Health Services

The segment provides pharmacy benefits management through CVS Caremark and delivers care in medical clinics, virtually and in the home. Its work covers plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical and disease management services, medical spend management and administrative services for providers and for entities covered by the federal 340B drug pricing program. It runs a group purchasing organisation that negotiates pricing and rebates with drug manufacturers, and its Cordavis subsidiary works with manufacturers on biosimilar products. Health care delivery assets include Signify Health in health risk assessments and value-based care and Oak Street Health in value-based primary care for Medicare eligible patients. During 2025 the pharmacy benefits manager filled or managed 1.9 billion prescriptions on a 30-day equivalent basis.

Pharmacy and Consumer Wellness

The segment dispenses prescriptions in CVS Pharmacy retail locations and through infusion operations, runs patient care programmes and vaccination administration, and sells health and wellness products and general merchandise. It also handles fulfilment for the specialty and mail order pharmacy offerings of Health Services. Alongside the retail locations it operates online pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition. During 2025 it filled 1.8 billion prescriptions on a 30-day equivalent basis and dispensed approximately 28.5% of total retail pharmacy prescriptions in the United States. Front store categories cover over-the-counter drugs, consumer health, beauty, personal care and other general merchandise. The filing states that competition here runs mainly on store location and convenience, customer service, product selection and price, against drugstore chains, supermarkets, discount retailers, independent pharmacies, online retailers, membership clubs and mail order pharmacies.

Corporate and sourcing

Corporate/Other holds management and administrative costs supporting the whole group, including executive management, corporate relations, legal, compliance, human resources, finance, information technology, digital, data and analytics, together with acquisition-related transaction and integration costs, and it also holds products no longer sold to new customers such as large case pensions and long-term care insurance. Generic drug sourcing runs through Red Oak Sourcing, a venture owned half by the company and half by Cardinal Health, which negotiates generic supply contracts for both owners and holds no inventory itself. The company states that its workforce numbers more than 300,000 colleagues.

From CVS Health's annual report on Form 10-K for the year ended 31 December 2025. The filing

Written from the 10-K filed 10 February 2026: read the full 10-K.

The four quarters: Q1 FY2025 · Q2 FY2025 · Q3 FY2025 · Q4 FY2025

Income statement (profit and loss)

$ millionFY2025FY2024FY2023On the yearLast 8 years
Revenue402,067372,809357,776+7.8%
Cost of revenue221,167206,287217,098+7.2%
Gross profit180,900166,522140,678+8.6%
Gross margin45.0%44.7%39.3%
Operating income4,6608,51613,743-45.3%
Operating margin1.2%2.3%3.8%
Interest expense3,1192,9582,658+5.4%
Pre-tax income2,1366,14811,173-65.3%
Income tax4081,5622,805-73.9%
Effective tax rate19.1%25.4%25.1%
Net income1,7684,6148,344-61.7%
Net margin0.4%1.2%2.3%
Diluted EPS$1.39$3.66$6.47-62.0%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2025FY2024FY2023On the yearLast 8 years
Operating cash flow10,6399,10713,426+16.8%
Capital expenditure2,8322,7813,031+1.8%
Free cash flow7,8076,32610,395+23.4%
Free cash flow margin1.9%1.7%2.9%
Cash from investing-5,871-7,613-20,889
Cash from financing-4,940-1,1352,683
Depreciation and amortisation4,6064,5974,366+0.2%
Share-based compensation535540588-0.9%
Buybacks0.03,0232,012
Dividends paid3,3973,3733,132+0.7%
Dividend per share$2.66$2.66$2.420.0%
Diluted shares, weighted1,271m1,262m1,290m+0.7%
Shares outstanding at period end1,271m1,260m1,288m+0.9%

Balance sheet

$ millionFY2025FY2024FY2023On the yearLast 8 years
Shareholders' equity75,21475,56076,461-0.5%
Non-controlling interest168170175-1.2%
Debt64,57066,27061,610-2.6%
Operating lease liabilities13,64314,89916,034-8.4%
Finance lease liabilities1,2651,2951,325-2.3%
Other liabilities98,67895,02194,123+3.8%
Total liabilities and equity253,538253,215249,728+0.1%
Goodwill85,47891,27291,272-6.3%
Intangible assets25,50827,32329,234-6.6%
Investments34,81431,34126,278+11.1%
Cash and equivalents8,4538,5868,196-1.5%
Receivables39,77936,46935,227+9.1%
Inventory19,24618,10718,025+6.3%
Other assets40,26040,11741,496+0.4%
Total assets253,538253,215249,728+0.1%

10-K for the year ended 31 December 2025, filed 10 February 2026: the filing.